SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
NEW HIV DRUGS, FORMULATIONS, COMBINATIONS, AND RESISTANCE
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
DISCOVERY OF NOVEL POTENT HIV CAPSID INHIBITORS WITH LONG-ACTING POTENTIAL
Winston C Tse
Gilead Sciences, Foster City, CA, USA
HUMAN CONFIRMATION OF ORAL DOSE REDUCTION POTENTIAL OF NANOPARTICLE ARV FORMULATIONS
Andrew Owen
University of Liverpool, Liverpool, Merseyside, United Kingdom
CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR
Joseph M. Custodio
Gilead Science, Foster city, CA, USA
RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY
Paul E Sax
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
PATHWAYS OF RESISTANCE IN SUBJECTS FAILING DOLUTEGRAVIR MONOTHERAPY
José L Blanco
Hospital Clinic, Barcelona, Outside USA or Canada, Spain
PREVALENCE AND IMPACT OF PRETREATMENT DRUG RESISTANCE IN THE ANRS 12249 TASP TRIAL
Anne Derache
Africa Health Research Institute, Mtubatuba, South Africa
PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS
Josep M Llibre
Univ Hosp Germans Trias, Badalona, Barcelona, Spain
DORAVIRINE IS NON-INFERIOR TO DARUNAVIR/R IN PHASE 3 TREATMENT-NAÏVE TRIAL AT WEEK 48
Kathleen Squires
Thomas Jefferson University, Philadelphia, PA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
